 CAMBRIDGE, Mass., April 10, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today presented preclinical data from XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate ADC, and XMT-2056, an Immunosynthen-based STING-agonist ADC at the Virtual 2021 American Association for Cancer Research Annual Meeting being held from April 10-15th. 